ACADIA PHARMACEUTICALS INC — Director's Dealing 2021

Feb 8, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ACADIA PHARMACEUTICALS INC (ACAD)
CIK: 0001070494
Period of Report: 2021-02-04

Reporting Person: Stankovic Srdjan R. (President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-04	Common Stock	A	19231	$0.00	Acquired	39478	Direct
2021-02-04	Common Stock	S	8429	$50.61	Disposed	31049	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-04	Employee Stock Option (Right to Buy)	$29.59	A	15625	Acquired	2027-08-03	Common Stock (15625)	Direct
2021-02-04	Employee Stock Option (Right to Buy)	$35.80	A	21875	Acquired	2027-09-07	Common Stock (21875)	Direct
2021-02-04	Employee Stock Option (Right to Buy)	$21.28	A	11875	Acquired	2028-10-15	Common Stock (11875)	Direct

Footnotes

F1: On April 29, 2019, the reporting person was granted Restricted Stock Units (RSU's) that vest upon the Issuer's satisfaction of certain performance criteria. On February 4, 2021, the Issuer's Compensation Committee determined that certain performance criteria was achieved, resulting in the vesting of the RSU's as to the number of shares reported in column 4 of row 1 above.

F2: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

F3: On August 3, 2017, the reporting person was granted an option to purchase shares of common stock based upon and subject to the achievement of certain performance criteria. On February 4, 2021, the Issuer's Compensation Committee determined that certain performance criteria was achieved, resulting in the vesting of the option as to 15,625 shares.

F4: On September 7, 2017, the reporting person was granted an option to purchase shares of common stock based upon and subject to the achievement of certain performance criteria. On February 4, 2021, the Issuer's Compensation Committee determined that certain performance criteria was achieved, resulting in the vesting of the option as to 21,875 shares.

F5: On October 15, 2018, the reporting person was granted an option to purchase shares of common stock based upon and subject to the achievement of certain performance criteria. On February 4, 2021, the Issuer's Compensation Committee determined that certain performance criteria was achieved, resulting in the vesting of the option as to 11,875 shares.